대황과 실리마린의 병용투여의 간섬유화 보호 효과
Liver Protective Effect of the Co-treatment of Rhei Radix et Rhizoma and Silymarin on TAA-induced Liver Injury
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objective: Liver fibrosis is a highly conserved wound-healing response and the final common pathway of chronic inflammatory injury. This study aimed to evaluate the potential anti-fibrotic effect of the combination of Rhei Radix et Rhizoma water extract (RW) and silymarin in a thioacetamide (TAA)-induced liver fibrosis model. Methods: The liver fibrosis mouse model was established through the intraperitoneal injection of TAA (1 week 100 mg/kg, 2-3 weeks 200 mg/kg, 4-8 weeks 400 mg/kg) three times per week for eight weeks. Animal experiments were conducted in five groups; Normal, Control (TAA-induced liver fibrosis mice), Sily (silymarin 50 mg/kg), RSL (RW 50 mg/kg+silymarin 50 mg/kg), and RSH (RW 100 mg/kg+silymarin 50 mg/kg). Biochemical analyses were measured in serum, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), malondialdehyde (MDA), and ammonia levels. Liver inflammatory cytokines and fibrous biomarkers were measured by Western blot analysis, and liver histopathology was evaluated through tissue staining. Results: A significant decrease in the liver function markers AST and ALT and a reduction in ammonia and total bilirubin were observed in the group treated with RSL and RSH. Measurement of reactive oxygen species and MDA revealed a significant decrease in the RSL and RSH administration group compared to the TAA induction group. The expression of extracellular matrix-related proteins, such as transforming growth factor β1, α-smooth muscle actin, and collagen type I alpha 1, was likewise significantly decreased. All drug-administered groups had increased matrix metalloproteinase-9 but a decreasing tissue inhibitor of matrix metalloproteinase-1. RSL and RSH exerted a significant upregulation of NADPH oxidase 2, p22phox, and p47phox, which are oxidative stress-related factors. Furthermore, pro-inflammatory proteins such as cyclooxygenase 2 and interleukin-1β were markedly suppressed through the inhibition of nuclear factor kappa B activation. Conclusions: The administration of RW and silymarin suppressed the NADPH oxidase factor protein level and showed a tendency to reduce inflammation-related enzymes. These results suggest that the combined administration of RW and silymarin improves acute liver injury induced by TAA.
Abstract
Objective: Liver fibrosis is a highly conserved wound-healing response and the final common pathway of chronic inflammatory injury. This study aimed to evaluate the potential anti-fibrotic effect of the combination of Rhei Radix et Rhizoma water extract (RW) and silymarin in a thioacetamide (TAA)-induced liver fibrosis model. Methods: The liver fibrosis mouse model was established through the intraperitoneal injection of TAA (1 week 100 mg/kg, 2-3 weeks 200 mg/kg, 4-8 weeks 400 mg/kg) three times per week for eight weeks. Animal experiments were conducted in five groups; Normal, Control (TAA-induced liver fibrosis mice), Sily (silymarin 50 mg/kg), RSL (RW 50 mg/kg+silymarin 50 mg/kg), and RSH (RW 100 mg/kg+silymarin 50 mg/kg). Biochemical analyses were measured in serum, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), malondialdehyde (MDA), and ammonia levels. Liver inflammatory cytokines and fibrous biomarkers were measured by Western blot analysis, and liver histopathology was evaluated through tissue staining. Results: A significant decrease in the liver function markers AST and ALT and a reduction in ammonia and total bilirubin were observed in the group treated with RSL and RSH. Measurement of reactive oxygen species and MDA revealed a significant decrease in the RSL and RSH administration group compared to the TAA induction group. The expression of extracellular matrix-related proteins, such as transforming growth factor β1, α-smooth muscle actin, and collagen type I alpha 1, was likewise significantly decreased. All drug-administered groups had increased matrix metalloproteinase-9 but a decreasing tissue inhibitor of matrix metalloproteinase-1. RSL and RSH exerted a significant upregulation of NADPH oxidase 2, p22phox, and p47phox, which are oxidative stress-related factors. Furthermore, pro-inflammatory proteins such as cyclooxygenase 2 and interleukin-1β were markedly suppressed through the inhibition of nuclear factor kappa B activation. Conclusions: The administration of RW and silymarin suppressed the NADPH oxidase factor protein level and showed a tendency to reduce inflammation-related enzymes. These results suggest that the combined administration of RW and silymarin improves acute liver injury induced by TAA.
참고문헌 (31)
- Kisseleva T, "Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis", J Gastroenterology and Hepatology, 22(1), pp.78~88 (2007)
- Ramos-Tovar E, "Molecular Mechanisms that link oxidative stress, inflammation, and fibrosis in the liver", Antioxidants, 9(12), pp.1249~ (2020)
- Xu J, "The type of hepatic myofibroblasts contributing to liver fibrosis of different etiologies", Front Pharmacol, 5, pp.167~ (2014)
- Özdemir-Kumral ZN, "Potential effect of 1, 25 Dihydroxyvitamin D3 on thioacetamide-induced hepatotoxicity in rats", J Surg Res, 243, pp.165~172 (2019)
- 이진아, "Thioacetamide 유발 간 섬유화에 대한 모과의 효과", 한국식품영양과학회지, 50(8), pp.757~764 (2021), 한국식품영양과학회
- Muller A, "Thioacetamide-induced cirrhosis-like liver lesions in rats-usefulness and reliability of this animal model", Exp Pathol, 34(4), pp.229~236 (1998)
- Higashi T, "Hepatic stellate cells as key target in liver fibrosis", Adv Drug Deliv Rev, 121, pp.27~42 (2017)
- Breitkopf K, "TGF-beta", Smad signaling in the injured liver, 2006, pp.44(1), 57~66
- Hassan HA., "The Liver", pp.121~130 (2018), Academic Press
- Lieber CS, "Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons", J Clin Gastroenterol, 37(4), pp.336~339 (2003)
- Jeong JH, "A review on the medicinal potentials of Radix et Rhizoma Rhei", Journal of pharmacopuncture, 18(3), pp.7~16 (2015)
- Kiruthga PV, "Silymarin protection against major reactive oxygen species released by environmental toxins : exogenous H2O2 exposure in erythrocytes", Basic Clin Pharmacol Toxicol, 100(6), pp.414~419 (2007)
- Di Costanzo A, "Formulation strategies for Enhancing the Bioavailability of Silymarin : The state of the art", Molecules, 24(11), pp.2155~ (2019)
- Ju-Hee Song, "In Vitro Anti-Cariogenic Activity of Dichloromethane Fraction from Rheum undulatum L. Root", Archives of Pharmacal Research, 29(6), pp.490~496 (2006), 대한약학회
- Hwang IY, "A study on the Antigastric effects of Rheum Species Extracts and Their Active Components", Journal of food Hygiene and safety, 2(4), pp.330~336 (2013)
- Folin O, "On phosphotungasticphosphomolybdic compounds as color reagent", Journal of biological chemisty, 12(2), pp.239~243 (1912)
- Lister CE, "Developmental changes in the concentration and composition of flavonoids in skin of a red and a green apple cultivar", Journal of the science of food and agriculture, 64(2), pp.155~161 (1994)
- Blois MS, "Antioxidant determinations by the use of a stable free radical", Nature, 181(4617), pp.1199~1200 (1958)
- Re R, "Antioxidant activity applying an improved ABTS radical cation decolorizationassay", Free Radical Biology and Medicine, 26(9-10), pp.1231~1237 (1999)
- 박성민, "대황 추출물의 항산화 활성 및 MMP-1 저해 활성", 생명과학회지, 18(12), pp.1700~1704 (2008), 한국생명과학회
- Schuppan D, "Hepatic fibrosis : from bench to bedside", Journal Gastroenterol Hepatol, 17(3), pp.300~305 (2002)
- Sanchez-Valle V, "Role of oxidative stress and molecular changes in liver fibrosis : a review", Curr Med Chem, 19(28), pp.4850~4860 (2012)
- Parola M, "Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues", Mol Aspect Med, (65), pp.37~55 (2019)
- Kren V, "Silybin and Silymarin new effects and applications", Biomed Papers, 149(1), pp.29~41 (2005)
- Li Q, "Molecular Mechanism of Action of Emodin : As an Anti-Cardiovascular Disease Drug", Frontiers in Pharmacology, 11, pp.559607~ (2020)
- 김현정, "Immunological measurement of aspartate", alanine aminotransferase in predicting liver fibrosis and inflammation, 2020, pp.35(2), 320~330[DOI]
- Arriazu E, "Extracellular Matrix and Liver Disease", Antioxid. Redox Signal, 21(7), pp.1078~1097 (2014)
- Bataller R, "Hepatic stellate cells as a target for the treatment of liver fibrosis", Seminars in Liver Disease, 25(4), pp.419~431 (2005)
- Bataller R, "AngiotensinⅡinduces contraction and proliferation of human hepatic stellate cells", Gastroenterology, 118(6), pp.1149~1156 (2000)
- Bataller R, "NADPH oxidase signal transduces angiotensin II n in hepatic stellate cells and critical in hepatic fibrosis", J Clin Invest, 112(9), pp.1383~1394 (2003)
- De Souza Basso B, "Methoxyeugenol deactivates hepatic stellate cells and attenuates liver fibrosis and inflammation through a PPAR-ɣ and NF-kB mechanism", Journal of Ethnopharmacol, 280, pp.114433~ (2021)